Ovensa and Celanese to collaborate to advance precision drug delivery

Digitalization of pharma labs will help in better decision making: Experts

Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth

Jubilant HollisterStier enters into agreement of $149.6 mn with US Govt to expand critical vaccine manufacturing capacity

This agreement is in addition to the $92 million filling line expansion announced in November 2021

JBCL rebrands as JB

JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India

Excelra Partners with HotSpot Therapeutics to enhance allosteric drug discovery efforts

The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models

Moderna announces advancements in mRNA platform science for application across multiple diseases

Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery

First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial

CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng

Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up

Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins

‘One Step’ portal to provide information on medical tourism: Dr Mansukh Mandaviya

“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'

Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY

The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt